Riociguat denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for riociguat are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Deny Riociguat as "Not FDA-Approved"

Riociguat (Adempas) holds FDA approval for specific forms of pulmonary hypertension. However, BCBS may issue a "not FDA-approved" denial when the indication documented in your claim does not exactly match the approved labeling language, when the diagnosis code submitted is ambiguous, or when the clinical notes describe an off-label use. This is often a documentation problem rather than a true eligibility problem, and it is worth appealing.

## Why This Denial Is Appealable

FDA approval status must be evaluated against the specific indication on the prescribing label. If your prescriber is treating a condition that falls within the approved indication, a denial citing lack of FDA approval is factually incorrect and should be overturned on appeal. Even where use is off-label, many states and federal law (under ERISA and ACA plans) require coverage of off-label uses supported by recognized compendia or peer-reviewed literature. Confirm with your prescriber which category applies to your situation.

## Federal Appeal Framework

• Internal appeal: You have the right to a full internal appeal under ERISA §503 (employer plans) or ACA §2719 (marketplace/individual plans). File within the timeframe stated in your denial letter — typically 180 days.
• External review: If the internal appeal is denied, request an independent external review. Federal rules generally provide approximately four months from the internal denial to initiate external review. An accredited Independent Review Organization (IRO) will evaluate whether the denial is consistent with the plan terms and applicable law.
• Expedited review: If delaying treatment poses a serious risk to your health, request expedited external review — a decision is typically required within 72 hours.

## Documentation to Gather

• Diagnosis confirmation: Office notes, imaging, right-heart catheterization results, or specialist reports establishing the precise diagnosis and its classification.
• Prescriber letter: A detailed medical-necessity letter from your prescribing physician stating the exact FDA-approved indication being treated and citing the relevant section of the prescribing label.
• Prescribing label reference: Attach or quote the relevant indication section directly from the current FDA-approved label (available at DailyMed).
• Prior-treatment history: A chronological list of previously tried therapies with dates and documented outcomes.

## Criteria-Mapping Structure

Create a two-column table. In the left column, copy each requirement stated in BCBS's published coverage/medical policy for riociguat. In the right column, cite the exact chart entry, test result, or prescriber note that satisfies each requirement. Attach the relevant page of the FDA prescribing label alongside. This structure forces the reviewer to address each point individually and prevents a blanket re-denial.